Xintela Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • XINT

Stock Symbol

  • Share Price
  • $0.01
  • (As of Friday Closing)

Xintela General Information

Description

Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.

Contact Information

Website
www.xintela.se
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Medicon Village
  • 223 81 Lund
  • Sweden
+46 046-275
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Medicon Village
  • 223 81 Lund
  • Sweden
+46 046-275

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xintela Stock Performance

As of 13-Nov-2026, Xintela’s stock price is $0.01. Its current market cap is $12M with 861M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.01 $0.01 - $0.04 $12M 861M 235K

Xintela Financials Summary

As of 30-Jun-2026, Xintela has a trailing 12-month revenue of $323K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 16,809 21,378 19,841 14,204
Revenue 323 232 399 7
EBITDA (4,850) (4,690) (3,678) (5,031)
Net Income (5,096) (4,943) (3,706) (5,088)
Total Assets 3,612 3,154 2,248 1,841
Total Debt 3,087 2,173 1,858 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xintela Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xintela‘s full profile, request access.

Request a free trial

Xintela Patents

Xintela Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022277806-A1 Mesenchymal stem cells for use in the treatment of skin defects Active 20-May-2021
AU-2022277806-B2 Mesenchymal stem cells for use in the treatment of skin defects Active 20-May-2021
CA-3218101-A1 Mesenchymal stem cells for use in the treatment of skin defects Pending 20-May-2021
EP-4340854-A1 Mesenchymal stem cells for use in the treatment of skin defects Pending 20-May-2021
US-12599633-B2 Mesenchymal stem cells for use in the treatment of skin defects Active 20-May-2021 A61K35/28
To view Xintela’s complete patent history, request access »

Xintela Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xintela Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xintela‘s full profile, request access.

Request a free trial

Xintela ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Xintela’s complete esg history, request access »

Xintela Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Targinta Lund, Sweden 2018

Xintela FAQs

  • When was Xintela founded?

    Xintela was founded in 2009.

  • Where is Xintela headquartered?

    Xintela is headquartered in Lund, Sweden.

  • What is the size of Xintela?

    Xintela has 11 total employees.

  • What industry is Xintela in?

    Xintela’s primary industry is Drug Discovery.

  • Is Xintela a private or public company?

    Xintela is a Public company.

  • What is Xintela’s stock symbol?

    The ticker symbol for Xintela is XINT.

  • What is the current stock price of Xintela?

    As of 13-Nov-2026 the stock price of Xintela is $0.01.

  • What is the current market cap of Xintela?

    The current market capitalization of Xintela is $12M.

  • What is Xintela’s current revenue?

    The trailing twelve month revenue for Xintela is $323K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process